PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
HLB LifeScience's enterprise value hinges heavily on U.S. approval of the liver cancer drug rivoceranib, while consolidated revenue plunged and net losses widened sharply in 2025, adding to financial strain.
2025 consolidated revenue fell sharply to KRW 45.75 billion from KRW 102.24 billion a year earlier, while operating losses stayed above KRW 20 billion for a fourth straight year.
The rivoceranib-camrelizumab combination has entered a third FDA review after two prior Complete Response Letters, with a PDUFA goal date reported as July 23, 2026.
The planned absorption merger with HLB, resolved in April 2025, was withdrawn in August 2025 after appraisal-right payouts exceeded the contractual cap of KRW 40 billion.
In May 2026 the board decided to discontinue lower-margin OEM and in-vitro diagnostics operations to refocus the portfolio on higher value-added businesses.
Quarterly net profit swung from roughly -KRW 36.7 billion in 2025Q3 to about +KRW 20.1 billion in 2025Q4 before turning negative again, reflecting large non-operating volatility.
HLB LifeScience operates as a holding-company-like entity across four business lines—medicare, bio-development, medical devices, and energy—together with its consolidated subsidiaries.
The core bio asset is rivoceranib, an oral targeted anticancer agent inhibiting VEGFR-2, for which the company holds exclusive domestic rights along with a partial revenue share in Japan and Europe, as well as domestic marketing rights to pyrotinib, an EGFR-family inhibitor.
Subsidiary HLB LifeScience R&D discovers new anticancer compounds at its Dongtan drug research center and was recently selected as a demand enterprise for a government-backed AI drug discovery program to strengthen candidate-verification capabilities.
Another subsidiary, HLB Cell, holds a pipeline spanning bio-artificial liver, hemostatic agents, and human extracellular matrix products, while HLB Energy runs a waste incineration business in the southeastern region.
The medical device unit supplies disposable syringes, needles, and filter syringes to major domestic hospitals and veterinary clinics, exports to the United States, Mongolia, and Vietnam under FDA approval, and completed its first U.S. shipment of animal-use hard-pack syringes last year.
The OEM and in-vitro diagnostics (IVD) operations within the medicare division, hit by weakening post-pandemic demand and intensifying competition, were discontinued following a May 2026 board resolution.
The company also holds a 14% stake in HLB Pharma, a 3% stake in HLB Innovation, and 1.93 million HLB shares, linking its value to affiliated group companies.
An absorption merger with HLB, resolved in April 2025, was withdrawn in August 2025 after shareholder appraisal-right claims exceeded the contractual cap, leaving the two companies to continue operating as separate listed entities.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | — | -₩6.4B | — |
| 2025Q3 | ₩13.6B | -₩3.8B | −28.2% |
| 2025Q4 | ₩10.9B | -₩5.8B | −53.0% |
| 2026Q1 | ₩15.2B | -₩6.5B | −42.5% |
| 2026Q2 | ₩14.7B | -₩7.6B | −51.6% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩99.6B | -₩20.2B | -₩54.3B | −20.2% | −23.1% | 74.4% |
| 2023 | ₩98B | -₩24.5B | -₩6B | −25.0% | −2.6% | 83.2% |
| 2024 | ₩102.2B | -₩24.8B | ₩6.1B | −24.3% | 1.5% | 35.2% |
| 2025 | ₩45.8B | -₩22B | -₩99.8B | −48.1% | −33.6% | 60.6% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
Consolidated revenue stayed roughly in the KRW 100 billion range for three years—KRW 99.59 billion in 2022, KRW 97.99 billion in 2023, and KRW 102.24 billion in 2024—before plunging to KRW 45.75 billion in 2025.
Operating losses narrowed slightly from KRW 20.16 billion (2022) and KRW 24.53 billion (2023) to KRW 24.82 billion (2024) and then KRW 22.03 billion (2025), but the revenue collapse pushed the operating margin from -20.2% in 2022 to -48.1% in 2025.
Net profit attributable to owners swung from losses of KRW 54.28 billion (2022) and KRW 5.98 billion (2023) to a profit of KRW 6.14 billion in 2024, before reversing into a large loss of KRW 99.79 billion in 2025.
This swing was far larger than the change in operating results, pointing to significant non-operating items such as equity-method gains/losses or fair-value adjustments on financial instruments.
Over the most recent four quarters, owners' net loss reached about KRW 36.70 billion in 2025Q3 before turning to a profit of roughly KRW 20.08 billion in 2025Q4, then reverting to losses of KRW 7.80 billion in 2026Q1 and KRW 8.70 billion in 2026Q2.
Quarterly revenue recovered modestly from KRW 13.60 billion in 2025Q3 to KRW 15.20 billion in 2026Q1 and KRW 14.66 billion in 2026Q2, even as operating losses persisted in the KRW 6-7.6 billion range each quarter.
Operating cash flow has been negative for four consecutive years from 2022 through 2025, ranging from roughly -KRW 10 billion to -KRW 30 billion, underscoring weak core cash generation.
The debt ratio eased from 83.2% in 2023 to 35.2% in 2024 before rising again to 60.6% in 2025, showing volatility in balance-sheet stability metrics as well.
The global hepatocellular carcinoma (HCC) treatment market is projected by Grand View Research to grow at a 17.9% compound annual rate, reaching roughly USD 9.81 billion (about KRW 13 trillion) by 2030.
The current first-line market is led by Roche's Tecentriq plus Avastin and Bristol Myers Squibb's Opdivo plus Yervoy combinations, while the rivoceranib-camrelizumab regimen posted a median overall survival of 23.8 months in the CARES-310 Phase 3 trial, exceeding sorafenib (15.2 months), Tecentriq plus Avastin (19.2 months), and Opdivo plus Yervoy (23.7 months).
However, the combination has received two FDA Complete Response Letters, both attributed not to rivoceranib's efficacy or safety but to manufacturing and quality-control (CMC) issues at partner Hengrui Pharmaceutical's camrelizumab production facility.
This structure embeds a partner-dependent risk that the HLB group cannot directly control.
Within Korea's biotech sector, a growing number of companies are attempting self-developed, self-approved, and self-commercialized drugs rather than relying solely on licensing-out deals, and if approved, rivoceranib could be viewed as the first domestically developed anticancer drug to complete global trials and regulatory approval without an out-licensing deal.
Amid intensifying competition, manufacturing reliability and CMC readiness have emerged as a central variable determining regulatory success.
The rivoceranib-camrelizumab combination was resubmitted to the FDA for a third time in January 2026 and classified as Class 2, setting a PDUFA goal date of July 23, 2026, six months after resubmission.
Some outlets (medicaldaily, reported July 15, 2026) stated that a third CRL was issued on July 9, 2026, but also reported that the FDA concluded a facility inspection of Hengrui's manufacturing site with a 'Voluntary Action Indicated (VAI)' classification, removing the main obstacle—though this is a provisional media report and the official final outcome should be separately verified through DART disclosures.
The company has emphasized that both prior CRLs concerned CMC issues rather than efficacy or safety, and said it recruited a former Samsung Biologics executive in early 2026 to strengthen CMC response capabilities.
The cholangiocarcinoma candidate liraprugratinib has received FDA Breakthrough Therapy and Orphan Drug designations, and industry sources had projected a related approval decision around September 2026.
HLB's bio-strategy planning team has set a target of filing a European Medicines Agency (EMA) application for rivoceranib in the second half of 2026.
The company decided at a May 2026 board meeting to wind down its lower-margin OEM and IVD operations, stating it would focus the medical device unit on export expansion and higher value-added products.
Subsidiary HLB LifeScience R&D is pursuing preclinical-ready candidates through a government-backed AI drug discovery support program.
Rivoceranib-related entities have also secured large-scale overseas funding via an exchangeable bond arrangement with global asset manager LMR Partners, diversifying the company's financing channels regardless of the regulatory outcome.
The current share price trades at a certain premium to net asset value, suggesting the market is pricing in some value beyond tangible assets, likely tied to the drug pipeline.
However, the company has recently shifted into a large net-loss structure, making a price-to-earnings ratio incalculable, and valuation judgments depend far more on pipeline approval outcomes such as rivoceranib than on financial performance.
No dividend has been paid recently, meaning the investment case leans on pipeline catalysts rather than income appeal. The historical trading range has shown large swings tied to drug-approval news flow, suggesting similar volatility around regulatory events could persist going forward.
Given these characteristics, gauging enterprise value requires monitoring approval timelines and subsequent disclosures alongside financial metrics rather than relying on financial ratios alone.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
The rivoceranib-camrelizumab combination posted superior survival data versus standard care in its Phase 3 trial. The issues FDA has cited relate to partner manufacturing (CMC) rather than efficacy or safety, leaving a pathway to approval once resolved.
If approved, the drug could be recognized as a domestically developed, self-approved, and self-commercialized oncology asset without an out-licensing deal.
The company decided in May 2026 to discontinue lower-margin OEM and IVD operations as part of a shift toward higher value-added businesses. The medical device unit is accelerating export expansion, including to the U.S., with confirmed new shipments of animal-use products. If this restructuring continues, the share of lower-margin revenue could decline going forward.
The company holds a 14% stake in HLB Pharma, a 3% stake in HLB Innovation, and 1.93 million HLB shares, giving it exposure to affiliated group value. The cholangiocarcinoma candidate liraprugratinib has received FDA Breakthrough Therapy and Orphan Drug designations, providing a pipeline beyond rivoceranib. Large-scale funding secured from an overseas asset manager has also diversified financing channels.
Both prior CRLs stemmed from manufacturing issues at Chinese partner Hengrui's production facility, a factor the company cannot directly control. A repeat of similar findings in the third review cannot be ruled out. Renewed delay or another rejection could undermine market confidence in the pipeline's value.
Consolidated revenue in 2025 fell to less than half of the prior year's level, and operating losses have persisted for four straight years. Operating cash flow has also been negative for four consecutive years, reflecting weak core cash generation.
Because enterprise value depends so heavily on a single regulatory event, the earnings-based safety net remains thin.
The absorption merger with HLB was withdrawn in August 2025 due to the burden of appraisal-right payouts. As a result, the two companies remain separate legal entities, and rivoceranib's rights and revenue streams have not been fully unified. If a merger is pursued again, its success could once more hinge on share price levels and shareholder reaction.
The rivoceranib combination has already received two CRLs, and the outcome of the third review may again hinge on the partner's manufacturing facility. Other pipeline assets, such as the cholangiocarcinoma candidate, face separate approval procedures and timeline risk. Any delay or rejection would require a broad reassessment of business plans.
Operating cash flow has been negative for multiple years, indicating heavy reliance on external financing. Continued fundraising through instruments such as exchangeable bonds could affect shareholder value depending on future redemption or conversion terms. The debt ratio has also swung significantly year to year, warranting ongoing monitoring of financial stability.
Discontinuing OEM and IVD operations could further shrink the revenue base in the near term. If the shift toward higher value-added businesses does not proceed as planned, profitability improvements could be delayed.
Extensive business and equity linkages with affiliated group companies also raise the possibility of risk transmission from those entities.
Industry sources had projected an FDA approval decision for the cholangiocarcinoma candidate liraprugratinib around this time, warranting a check of related disclosures and announcements.
It is worth reconfirming via official disclosures whether the final FDA determination and any follow-up steps (such as a resubmission timeline) for the rivoceranib-camrelizumab combination, around the reported July 23, 2026 PDUFA goal date, have been formally settled.
It is worth tracking whether and when the company proceeds with its targeted European Medicines Agency (EMA) filing for rivoceranib.
The 2026Q3 consolidated earnings disclosure should be checked to see whether the revenue recovery trend and pattern of operating losses continue.
HLB LifeScience's enterprise value is heavily tied to a single event—U.S. approval of the rivoceranib-camrelizumab combination—and since both prior CRLs stemmed from partner manufacturing issues, the outcome of the third review remains a matter requiring confirmation.
Financially, 2025 revenue fell to less than half of the prior year's level with a large net loss, and operating cash flow has stayed negative for multiple years, pointing to a weak core earnings base.
The absorption merger with HLB was withdrawn due to the burden of appraisal-right payouts, meaning the intended governance simplification has not yet materialized, and the two companies continue to operate as separate entities.
The company is attempting to improve its business mix through portfolio restructuring, including winding down lower-margin OEM and IVD operations and expanding medical device exports, while also holding a follow-on pipeline asset in the cholangiocarcinoma candidate liraprugratinib.
For investors, a comprehensive approach that tracks not only financial metrics but also regulatory events—the final rivoceranib approval outcome, the cholangiocarcinoma candidate's approval timeline, and progress on the EMA filing—appears warranted.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.